Recent developments with Emergent Biosolutions Inc (EBS) have led to the company’s beta value being reach 1.59 cents.

On Friday, Emergent Biosolutions Inc (NYSE: EBS) opened higher 3.55% from the last session, before settling in for the closing price of $8.45. Price fluctuations for EBS have ranged from $1.42 to $15.10 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 10.59%. Company’s average yearly earnings per share was noted 71.54% at the time writing. With a float of $51.92 million, this company’s outstanding shares have now reached $52.20 million.

The extent of productivity of a business whose workforce counts for 1600 workers is very important to gauge. In terms of profitability, gross margin is 22.99%, operating margin of -36.59%, and the pretax margin is -52.45%.

Emergent Biosolutions Inc (EBS) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Emergent Biosolutions Inc is 3.89%, while institutional ownership is 56.45%. The most recent insider transaction that took place on Jun 04 ’24, was worth 61,100. In this transaction Director of this company sold 10,000 shares at a rate of $6.11, taking the stock ownership to the 54,482 shares. Before that another transaction happened on May 29 ’24, when Company’s Director sold 1,830 for $4.61, making the entire transaction worth $8,436. This insider now owns 64,482 shares in total.

Emergent Biosolutions Inc (EBS) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 71.54% per share during the next fiscal year.

Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators

Check out the current performance indicators for Emergent Biosolutions Inc (EBS). In the past quarter, the stock posted a quick ratio of 0.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43. Likewise, its price to free cash flow for the trailing twelve months is 12.57.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -11.25, a number that is poised to hit 0.10 in the next quarter and is forecasted to reach 1.51 in one year’s time.

Technical Analysis of Emergent Biosolutions Inc (EBS)

The latest stats from [Emergent Biosolutions Inc, EBS] show that its last 5-days average volume of 1.29 million was inferior to 3.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 50.91%. Additionally, its Average True Range was 0.79.

During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 40.04%, which indicates a significant decrease from 73.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.95% in the past 14 days, which was lower than the 159.06% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.24, while its 200-day Moving Average is $5.39. Now, the first resistance to watch is $9.07. This is followed by the second major resistance level at $9.40. The third major resistance level sits at $9.71. If the price goes on to break the first support level at $8.43, it is likely to go to the next support level at $8.12. The third support level lies at $7.79 if the price breaches the second support level.

Emergent Biosolutions Inc (NYSE: EBS) Key Stats

There are currently 52,402K shares outstanding in the company with a market cap of 472.68 million. Presently, the company’s annual sales total 1,049 M according to its annual income of -760,500 K. Last quarter, the company’s sales amounted to 254,700 K and its income totaled -283,100 K.